< Back to previous page
Researcher
Thaïs Baert
- Disciplines:Oncology, Immunology
Affiliations
- Laboratory for Tumor Immunology and Immunotherapy (Division)
Member
From1 Sep 2016 → 31 Dec 2020
Publications
1 - 10 of 44
- Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience(2022)
Authors: Thaïs Baert
Number of pages: 8 - Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer(2021)
Authors: Christine De Bruyn, Jolien Ceusters, Thaïs Baert, Ann Vankerckhoven, Roxanne Wouters, Dominique Schols, Dirk Timmerman, Ignace Vergote, An Coosemans
Number of pages: 13 - Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation-real life data(2021)
Authors: Thaïs Baert
Pages: 569 - 577Number of pages: 9 - Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer(2021)
Authors: Jenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, Daniel Borras Morales, Yani Berckmans, Roxanne Wouters, Thaïs Baert, Thomas Holland Bourne, Wouter Froyman, Dominique Schols, et al.
Number of pages: 18 - The systemic treatment of recurrent ovarian cancer revisited.(2021)
Authors: Thaïs Baert
Pages: 710 - 725 - Type of chemotherapy has substantial effects on the immune system in ovarian cancer(2021)
Authors: Ann Vankerckhoven, Thaïs Baert, Matteo Riva, Christine De Bruyn, Jolien Ceusters, Ignace Vergote, An Coosemans
Number of pages: 8 - Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience(2021)
Authors: Thaïs Baert
Pages: 975 - 984Number of pages: 10 - Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients(2021)
Authors: Thaïs Baert
Pages: 1021 - 1032Number of pages: 12 - Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study(2020)
Authors: Thaïs Baert
Pages: 434 - 441Number of pages: 8 - Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?(2020)
Authors: Thaïs Baert
Pages: 932 - 940Number of pages: 9